Kidney study findings could boost the market for embolic protection devices
This article was originally published in Clinica
In what could boost sales of coronary embolic protection devices, an independent study has found that such devices may also be used to successfully remove harmful emboli in blood vessels supplying the kidney during routine angioplasty and stenting. In current procedures, emboli - abnormal particles such as blood clots that clog-up the vessel - can become dislodged and cause further harm elsewhere. If the devices can gain worldwide approval for this new indication, their use could be expanded to a further 100,000 procedures a year.
You may also be interested in...
Lannett will launch a further seven products in fiscal 2021, after launching four products recently in the first quarter of FY21. The company also plans to pay off its Term Loan ‘A’ in full, by the end of November 2020.
Pfizer has now received a formal European Commission approval for its Nyvepria biosimilar pegfilgrastim. The approval puts the firm in direct competition with several other versions of the Neulasta original.
AstraZeneca's research head admits that the half dose approach was a lucky mistake - but one that could boost the vaccine's effectiveness and supplies. The US regulator may not be persuaded, however.